ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis
USA - NASDAQ:ACAD - US0042251084 - Common Stock
23.8 USD
-0.21 (-0.87%)
23.3 USD
-0.5 (-2.1%)
We assign a fundamental rating of 5 out of 10 to ACAD. ACAD was compared to 533 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
ACAD had a positive operating cash flow in the past year.
ACAD had negative earnings in each of the past 5 years.
In the past 5 years ACAD always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 13.80%, ACAD belongs to the best of the industry, outperforming 94.93% of the companies in the same industry.
The Return On Equity of ACAD (20.57%) is better than 95.87% of its industry peers.
With an excellent Return On Invested Capital value of 3.36%, ACAD belongs to the best of the industry, outperforming 90.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.8% | ||
| ROE | 20.57% | ||
| ROIC | 3.36% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ACAD (32.30%) is better than 96.44% of its industry peers.
ACAD has a better Operating Margin (7.28%) than 90.43% of its industry peers.
ACAD has a Gross Margin of 178.93%. This is amongst the best in the industry. ACAD outperforms 99.25% of its industry peers.
ACAD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.28% | ||
| PM (TTM) | 32.3% | ||
| GM | 178.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
ACAD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ACAD has more shares outstanding
Compared to 5 years ago, ACAD has more shares outstanding
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 4.66 indicates that ACAD is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.66, ACAD is in the better half of the industry, outperforming 74.67% of the companies in the same industry.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.66 |
ROIC/WACC0.38
WACC8.77%
2.3 Liquidity
A Current Ratio of 2.91 indicates that ACAD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.91, ACAD is doing worse than 64.17% of the companies in the same industry.
A Quick Ratio of 2.83 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has a Quick ratio of 2.83. This is in the lower half of the industry: ACAD underperforms 63.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 |
3. Growth
3.1 Past
The earnings per share for ACAD have decreased strongly by -14.10% in the last year.
Looking at the last year, ACAD shows a very strong growth in Revenue. The Revenue has grown by 67.12%.
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)67.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
3.2 Future
Based on estimates for the next years, ACAD will show a very strong growth in Earnings Per Share. The EPS will grow by 39.38% on average per year.
The Revenue is expected to grow by 9.84% on average over the next years. This is quite good.
EPS Next Y21.55%
EPS Next 2Y35.04%
EPS Next 3Y37.81%
EPS Next 5Y39.38%
Revenue Next Year10.06%
Revenue Next 2Y10.93%
Revenue Next 3Y10.69%
Revenue Next 5Y9.84%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 35.52, ACAD can be considered very expensive at the moment.
Based on the Price/Earnings ratio, ACAD is valued cheaper than 91.56% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.51, ACAD is valued a bit more expensive.
The Price/Forward Earnings ratio is 27.19, which means the current valuation is very expensive for ACAD.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaply inside the industry as 91.18% of the companies are valued more expensively.
ACAD is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.52 | ||
| Fwd PE | 27.19 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 90.81% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ACAD is valued cheaper than 92.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 45.45 | ||
| EV/EBITDA | 52.98 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ACAD may justify a higher PE ratio.
ACAD's earnings are expected to grow with 37.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.65
PEG (5Y)N/A
EPS Next 2Y35.04%
EPS Next 3Y37.81%
5. Dividend
5.1 Amount
No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.8
-0.21 (-0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.78%
Inst Owner Change1.46%
Ins Owners0.3%
Ins Owner Change-1.75%
Market Cap4.02B
Revenue(TTM)-804.00K
Net Income(TTM)169.18M
Analysts77.04
Price Target29.74 (24.96%)
Short Float %5.07%
Short Ratio4.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.63%
Min EPS beat(2)-3.19%
Max EPS beat(2)14.46%
EPS beat(4)2
Avg EPS beat(4)-13.96%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)7.72%
EPS beat(12)7
Avg EPS beat(12)13.12%
EPS beat(16)10
Avg EPS beat(16)17.21%
Revenue beat(2)1
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.93%
Max Revenue beat(2)0.08%
Revenue beat(4)1
Avg Revenue beat(4)-2.63%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)4
Avg Revenue beat(8)-0.28%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)7
Avg Revenue beat(16)-1.31%
PT rev (1m)0.35%
PT rev (3m)1.91%
EPS NQ rev (1m)-2.1%
EPS NQ rev (3m)4.39%
EPS NY rev (1m)1.81%
EPS NY rev (3m)9.06%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)0.05%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)0.74%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.52 | ||
| Fwd PE | 27.19 | ||
| P/S | 7.67 | ||
| P/FCF | 45.45 | ||
| P/OCF | 21.36 | ||
| P/B | 4.88 | ||
| P/tB | 5.67 | ||
| EV/EBITDA | 52.98 |
EPS(TTM)0.67
EY2.82%
EPS(NY)0.88
Fwd EY3.68%
FCF(TTM)0.52
FCFY2.2%
OCF(TTM)1.11
OCFY4.68%
SpS3.1
BVpS4.87
TBVpS4.2
PEG (NY)1.65
PEG (5Y)N/A
Graham Number8.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.8% | ||
| ROE | 20.57% | ||
| ROCE | 4.26% | ||
| ROIC | 3.36% | ||
| ROICexc | 22.56% | ||
| ROICexgc | 156.96% | ||
| OM | 7.28% | ||
| PM (TTM) | 32.3% | ||
| GM | 178.93% | ||
| FCFM | 16.87% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score7
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 729.13% | ||
| Cap/Sales | 19.03% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 362.87% | ||
| Profit Quality | 52.22% | ||
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 | ||
| Altman-Z | 4.66 |
F-Score7
WACC8.77%
ROIC/WACC0.38
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y21.55%
EPS Next 2Y35.04%
EPS Next 3Y37.81%
EPS Next 5Y39.38%
Revenue 1Y (TTM)67.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year10.06%
Revenue Next 2Y10.93%
Revenue Next 3Y10.69%
Revenue Next 5Y9.84%
EBIT growth 1Y532.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.53%
EBIT Next 3Y32.73%
EBIT Next 5Y43.57%
FCF growth 1Y218.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y647.78%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the ChartMill fundamental rating of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ACAD.
Can you provide the valuation status for ACADIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What is the earnings growth outlook for ACADIA PHARMACEUTICALS INC?
The Earnings per Share (EPS) of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 21.55% in the next year.